Regeneron Pharmaceuticals
REGN
1,095 hedge funds and large institutions have $64.2B invested in Regeneron Pharmaceuticals in 2022 Q1 according to their latest regulatory filings, with 133 funds opening new positions, 384 increasing their positions, 405 reducing their positions, and 107 closing their positions.
47% more funds holding in top 10
Funds holding in top 10: 15 → 22 (+7)
24% more first-time investments, than exits
New positions opened: 133 | Existing positions closed: 107
13% more capital invested
Capital invested by funds: $56.6B → $64.2B (+$7.57B)
1% more funds holding
Funds holding: 1,080 → 1,095 (+15)
1.3% more ownership
Funds ownership: 85.34% → 86.65% (+1.3%)
5% less repeat investments, than reductions
Existing positions increased: 384 | Existing positions reduced: 405
38% less call options, than puts
Call options by funds: $698M | Put options by funds: $1.12B
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Dodge & Cox
San Francisco,
California
|
+$1.24B |
| 2 |
Capital International Investors
Los Angeles,
California
|
+$897M |
| 3 |
Capital World Investors
Los Angeles,
California
|
+$396M |
| 4 |
JP Morgan Chase
New York
|
+$236M |
| 5 |
State Street
Boston,
Massachusetts
|
+$206M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SGA
Sustainable Growth Advisers
Stamford,
Connecticut
|
-$307M |
| 2 |
Barclays
London,
United Kingdom
|
-$208M |
| 3 |
PI
Putnam Investments
Boston,
Massachusetts
|
-$157M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$155M |
| 5 |
Harris Associates
Chicago,
Illinois
|
-$144M |
REGN Hedge Fund Activity: Q1 2022 in Review
1,095 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Regeneron Pharmaceuticals (REGN) for Q1 2022, worth a combined $64.2B — up 13% from $56.6B a quarter earlier.
Buyers outnumbered sellers: 133 funds opened new REGN positions and 107 closed out — a net gain of 26 holders — while 384 added to existing stakes and 405 trimmed.
The largest buyer was Dodge & Cox, adding an estimated $1.24B. The largest seller was Sustainable Growth Advisers, cutting an estimated $307M.
- 1,095 institutional investors held Regeneron Pharmaceuticals (REGN) as of Q1 2022, up from 1,080 in Q4 2021.
- Funds reported $64.2B of Regeneron Pharmaceuticals stock for Q1 2022, up 13% quarter-over-quarter.
- 133 funds opened new Regeneron Pharmaceuticals positions in Q1 2022 and 107 closed out, a net change of +26 holders.
- The largest Regeneron Pharmaceuticals buyer in Q1 2022 was Dodge & Cox, an estimated $1.24B added.
- The largest Regeneron Pharmaceuticals seller in Q1 2022 was Sustainable Growth Advisers, an estimated $307M sold.
Based on aggregated 13F filings for Q1 2022.